• 027059

    Modern Treatment of Skull Base Chordomas:  From Endoscopes to Genetics


    Eric Wang, Paul Gardner, Carl Snyderman, Georgios Zenonos


    Introduction: Chordoma is a rare bony malignancy that commonly involves the clivus.  Radical surgical resection remains the most proven treatment and endoscopic endonasal approaches (EEA) have shown great promise. Variations in long-term prognosis are not well predicted with basic histological parameters.

    Objective: To study the efficacy of EEA in a large series of clival chordoma and evaluate molecular parameters that might predict prognosis.

    Methods: Medical record review was performed looking at outcomes of EEA for chordoma and evaluating recurrence based on multiple molecular parameters.

    Results: Until 2015, 106 patients underwent 151 EEAs for cranial base chordoma at UPMC.   The gross total resection (GTR) rate for primary tumors was 73%, with GTR rates for all tumors increasing steadily with experience.  Inferior and lateral tumor extensions remain a challenge and may require other approaches to achieve GTR. New or worsened cranial nerve palsies only occurred in 8% of cases.

    Tumors can be divided into 3 prognostic categories based on FISH for 1p36 and 9p21: those with 1p36 0-15% and 9p21 0-3% have a good prognosis and can perhaps withhold adjuvant radiation; those with 1p36>15% and 9p21>25% have a very poor prognosis and should be considered for experimental chemo- or immunotherapies in addition to radiotherapy.  The remaining majority of patients are currently treated with standard postoperative radiation.

    Conclusions: Cranial base chordoma treatment has expanded rapidly over the last 2 decades.  A combination of development and refinement of EEAs and improving molecular understanding of this rare tumor is driving their modern treatment paradigm.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy